

Papagudi Ganesan Subramanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1967992/publications.pdf>

Version: 2024-02-01

99
papers

664
citations

758635

12
h-index

752256

20
g-index

102
all docs

102
docs citations

102
times ranked

926
citing authors

#	ARTICLE	IF	CITATIONS
1	Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-cell lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease. <i>British Journal of Haematology</i> , 2022, 196, 374-379.	1.2	3
2	Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients. <i>Immunology and Cell Biology</i> , 2022, 100, 61-73.	1.0	6
3	Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 207-222.	1.8	2
4	Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B-cell acute lymphoblastic leukemia using multicolor flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, , .	0.7	3
5	Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India. <i>Frontiers in Oncology</i> , 2022, 12, 779230.	1.3	5
6	Copy number gain of <i>JAK2</i> on marker chromosome in a case of relapsed pediatric B-ALL. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29658.	0.8	2
7	Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-cell lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 434-445.	0.7	9
8	Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 421-433.	0.7	14
9	Cytogenetic profile and outcome of a pediatric acute promyelocytic leukemia patient presenting with isolated isochromosome 17q in absence of RARA rearrangement. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102443.	0.6	0
10	Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential premyelomastocytic leukemia condition. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 331-344.	0.7	2
11	Sudden blast phase in pediatric chronic myeloid leukemia—chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 345-351.	0.7	6
12	Utility of <i>CD36</i> as a novel addition to the immunophenotypic signature of <i>RAM</i> -phenotype acute myeloid leukemia and study of its clinicopathological characteristics. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 206-217.	0.7	7
13	Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD. <i>Transplant Infectious Disease</i> , 2021, 23, e13576.	0.7	5
14	Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. <i>Blood Advances</i> , 2021, 5, 1178-1193.	2.5	19
15	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). <i>Leukemia</i> , 2021, 35, 1392-1404.	3.3	51
16	Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INWARD) of the Hematology Cancer Consortium (HCC). <i>British Journal of Haematology</i> , 2021, 193, e1-e4.	1.2	9
17	A novel case of intrachromosomal amplification and insertion of <i>RUNX1</i> on derivative chromosome 2 in pediatric AML. <i>Cancer Genetics</i> , 2021, 254-255, 65-69.	0.2	2
18	Importance of conventional cytogenetics in the identification of <i>ins(19;X)(q13.1;p11.2q28)</i> and <i>t(1;11)(q10;p10)</i> , both, novel cytogenetic abnormalities in a pediatric AML case. <i>Cancer Genetics</i> , 2021, 256-257, 17-20.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)â€”A realâ€”world context. International Journal of Laboratory Hematology, 2021, 43, 1531-1538.	0.7	4
20	Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3436-3444.	2.5	6
21	Expression of CD304/neuropilinâ€”1 in adult Bâ€”cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. International Journal of Laboratory Hematology, 2021, 43, 990-999.	0.7	4
22	Improved protocol for plasma microRNA extraction and comparison of commercial kits. Biochemia Medica, 2021, 31, 467-475.	1.2	6
23	Clinical characteristics, laboratory parameters and outcomes of COVIDâ€”19 in cancer and nonâ€”cancer patients from a tertiary Cancer Centre in India. Cancer Medicine, 2021, 10, 8777.	1.3	4
24	Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia. Indian Journal of Medical Research, 2021, 153, 475.	0.4	1
25	Isodermivative chromosome 17 with multiple copies of RARâ€”1â€”PML fusions and Tp53 deletion in a rare case of APML. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 248-250.	0.6	0
26	Investigating the clinical, hematological and cytogenetic profile of endoreduplicated hypodiploids in BCP-ALL. Blood Cells, Molecules, and Diseases, 2020, 85, 102465.	0.6	2
27	Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. JCO Global Oncology, 2020, 6, 1684-1695.	0.8	11
28	Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma. International Journal of Hematology, 2020, 112, 835-840.	0.7	3
29	Over expression of brain and acute leukemia, cytoplasmic and ETSâ€”related gene is associated with poor outcome in acute myeloid leukemia. Hematological Oncology, 2020, 38, 808-816.	0.8	1
30	CD304/neuropilinâ€”1 is a very useful and dependable marker for the measurable residual disease assessment of Bâ€”cell precursor acute lymphoblastic leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 328-335.	0.7	13
31	Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. Journal of Pediatric Hematology/Oncology, 2020, 42, 415-419.	0.3	4
32	Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. , 2020, 8, e000630.		30
33	Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. Frontiers in Oncology, 2020, 10, 577.	1.3	13
34	Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematolymphoid malignancies. International Journal of Research in Medical Sciences, 2020, 8, 1556.	0.0	0
35	Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study. Blood, 2020, 136, 26-26.	0.6	0
36	Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing. Blood, 2020, 136, 5-6.	0.6	0

#	ARTICLE	IF	CITATIONS
37	There Is Still A Ray Of Hope. Pediatric Hematology Oncology Journal, 2019, 4, S4-S5.	0.1	0
38	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context. Frontiers in Oncology, 2019, 9, 450.	1.3	14
39	Evaluation of CD319 (SLAMF7) as a Novel Gating Marker for Plasma Cells in Flow Cytometric Immunophenotyping of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e153.	0.2	0
40	Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e357.	0.2	1
41	A Comprehensive Serum MicroRNA Profiling in Indian Multiple Myeloma Patients Uniformly Treated With VCD-Protocol. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e80.	0.2	0
42	Prognostic Relevance of the Proportion of Residual Polyclonal Plasma Cells in the Diagnostic Bone Marrow of Newly Diagnosed Multiple Myeloma Patients Managed Without Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e238-e239.	0.2	0
43	Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC). Blood, 2019, 134, 1306-1306.	0.6	6
44	Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome. Blood, 2019, 134, 2585-2585.	0.6	1
45	A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia. Blood, 2019, 134, 2710-2710.	0.6	0
46	Genomic Landscape of Juvenile Myelomonocytic Leukemia: A Real World Context. Blood, 2019, 134, 1728-1728.	0.6	0
47	Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry Part B - Clinical Cytometry, 2018, 94, 509-519.	0.7	14
48	Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; OOB: 000—000. Cytometry Part B - Clinical Cytometry, 2018, 94, 100-111.	0.7	47
49	A rare case of hepatosplenic T-cell lymphoma expressing CD19 with ring chromosome 7 and trisomy 8. Cancer Genetics, 2018, 228-229, 17-20.	0.2	11
50	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in <i>NPM1</i> mutated acute myeloid leukemia. Oncotarget, 2018, 9, 36613-36624.	0.8	26
51	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. Indian Journal of Cancer, 2018, 55, 9.	0.2	9
52	Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 503.	0.1	1
53	Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian Journal of Pathology and Microbiology, 2018, 61, 209.	0.1	8
54	BRAFV600E mutation in hairy cell leukemia: A single-center experience. Indian Journal of Pathology and Microbiology, 2018, 61, 532.	0.1	2

#	ARTICLE	IF	CITATIONS
55	Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 58.	0.1	0
56	Bortezomib in Combination with Cyclophosphamide and G-CSF for Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 2067-2067.	0.6	1
57	Immunophenotypic Assessment of Minimal Residual Disease in Younger Acute Myeloid Leukemia Patients Is Highly Predictive of Outcome. <i>Blood</i> , 2018, 132, 1498-1498.	0.6	0
58	CD19 negative precursor B acute lymphoblastic leukemia (B α CALL) α ” Immunophenotypic challenges in diagnosis and monitoring: A study of three cases. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 315-318.	0.7	13
59	Synchronous Presentation of Smoldering Multiple Myeloma (SMM) and Polycythemia Vera (PV)-A Rare Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e151.	0.2	0
60	Absolute Lymphocyte Count and Ratio of Absolute Lymphocyte Count/Absolute Monocyte Count (ALC/AMC) Provides a Readily Available Prognostic Indicator in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e101.	0.2	0
61	Utility of the New Versus Old Immunophenotypic Markers in the Flow Cytometric Immunophenotyping of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e92-e93.	0.2	0
62	Flow Cytometric Immunophenotyping in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia Demonstrates Characteristic Antigen Expression Pattern. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e51-e52.	0.2	0
63	Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet. <i>Current Protocols in Cytometry</i> , 2017, 80, 6.38.1-6.38.15.	3.7	9
64	Role of Multicolor Flow Cytometry in Assessing Bone Marrow Involvement by Solitary Plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e25.	0.2	0
65	Transient abnormal myelopoiesis: A case series and review of the literature. <i>Pediatric Hematology Oncology Journal</i> , 2017, 2, 14-18.	0.1	2
66	SLAM Family Member α CD229 α A Novel Gating Marker for Plasma Cells in Flow Cytometric Immunophenotyping (FCI) of Multiple Myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e19.	0.2	1
67	MOLECULAR HETEROGENEITY IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE CENTRE EXPERIENCE FROM INDIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018002.	0.5	9
68	Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 303-315.	0.3	6
69	Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital. <i>Indian Journal of Cancer</i> , 2017, 54, 609.	0.2	15
70	A rare extramedullary and extralymphoid presentation of mixed phenotypic blastic hematolymphoid neoplasm: A study of two cases. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 394.	0.1	5
71	An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia. <i>Indian Journal of Pathology and Microbiology</i> , 2017, 60, 209.	0.1	12
72	Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature. <i>Indian Journal of Pathology and Microbiology</i> , 2017, 60, 84-86.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Immunogenetics of chronic lymphocytic leukemia. Indian Journal of Pathology and Microbiology, 2017, 60, 38-42.	0.1	5
74	Development of a cost-effective duplexed real-time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes. International Journal of Laboratory Hematology, 2016, 38, e102-e106.	0.7	1
75	A novel and easy FxCycle violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 281-291.	1.1	23
76	Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 353-359.	1.1	31
77	Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. Leukemia and Lymphoma, 2016, 57, 2653-2660.	0.6	13
78	'Childhood systemic mastocytosis associated with t(8; 21) (q22; q22) acute myeloid leukemia'. Indian Journal of Pathology and Microbiology, 2016, 59, 407.	0.1	2
79	Lymphoblastic leukemia with surface light chain restriction: A diagnostic dilemma. Indian Journal of Pathology and Microbiology, 2016, 59, 410.	0.1	1
80	Plasmacytoid Dendritic Cell Levels at End of Induction Are Predictive of MRD Clearance and Also Influence Disease Outcome in a Subset of Patients. Blood, 2016, 128, 5263-5263.	0.6	0
81	Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 3.	0.1	16
82	MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leukemia and Lymphoma, 2015, 56, 420-425.	0.6	16
83	Sorafenib Combined with Non-Conventional Chemotherapy Produces Deep Remissions in FMS-like Tyrosine Kinase-3 Gene / Internal Tandem Duplication Positive (FLT-3 / ITD+) Acute Myeloid Leukemia (AML) Patients. Blood, 2015, 126, 4939-4939.	0.6	1
84	Blastic plasmacytoid dendritic cell neoplasm: Report of two pediatric cases. Indian Journal of Pathology and Microbiology, 2015, 58, 72.	0.1	6
85	Unusual immunophenotype of T-cell large granular lymphocytic leukemia: Report of two cases. Indian Journal of Pathology and Microbiology, 2015, 58, 108.	0.1	0
86	Plasmacytoid Dendritic Cell Burden in the Bone Marrow Predicts End of Induction Minimal Residual Disease Status in Adult Acute Myeloid Leukemia. Blood, 2015, 126, 2582-2582.	0.6	0
87	An Integrated Genomic Classification That Includes Copy Number Alterations Is Highly Predictive of Post Induction Minimal Residual Disease (MRD) Status in Childhood Precursor B Lineage Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2615-2615.	0.6	0
88	Pharmacokinetic and Pharmacodynamic Properties of a Biosimilar Rituximab (Reditux) Are Identical to the Innovator Brand MabThera Experience from a Tertiary Cancer Centre in Western India. Blood, 2014, 124, 2246-2246.	0.6	6
89	Anaplastic lymphoma kinase-positive large B-cell lymphoma: Unusual clinical and immunophenotypic features. Indian Journal of Dermatopathology and Diagnostic Dermatology, 2014, 1, 75.	0.0	0
90	Minimal Residual Disease by Multiparametric Flow Cytometry Predicts Relapse Free Survival better than Over-Expression of WT1 and BAALC in Acute Myeloid Leukemia. Blood, 2014, 124, 1064-1064.	0.6	0

#	ARTICLE	IF	CITATIONS
91	<i>BCR-ABL1</i> kinase domain mutations: Methodology and clinical evaluation. American Journal of Hematology, 2012, 87, 298-304.	2.0	50
92	Cytogenetic study in CML. Indian Journal of Medical Research, 2012, 135, 12.	0.4	5
93	Immunophenotypic profile of plasma cell leukemia: A retrospective study in a reference cancer center in India and review of literature. Indian Journal of Pathology and Microbiology, 2011, 54, 294.	0.1	10
94	Comparison of platelet counts by CellDyn Sapphire (Abbot Diagnostics), LH750 (Beckman Coulter), ReaPanThrombo immunoplatelet method (ReaMetrix), and the international flow reference method, in thrombocytopenic blood samples. Cytometry Part B - Clinical Cytometry, 2010, 78B, 279-285.	0.7	6
95	Diagnostic Utility of CD200 and CD43 Co-Expression by Flow Cytometry In Differentiating Chronic Lymphocytic Lymphoma From Other of Mature B Cell Non Hodgkin's Lymphoma.. Blood, 2010, 116, 4615-4615.	0.6	3
96	Diversity amongst various guidelines for immunophenotyping. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 560-561.	1.1	1
97	National Meeting on Guidelines for Immunophenotyping of Hematolymphoid Neoplasms in India. Cytometry Part B - Clinical Cytometry, 2009, 76B, 156-157.	0.7	0
98	Intracytoplasmic antigen study by flow cytometry in hematolymphoid neoplasm. Indian Journal of Pathology and Microbiology, 2009, 52, 135.	0.1	7
99	Immunophenotypic Profile of Acute Leukemia: Critical Analysis and Insights Gained at a Tertiary Care Center in India. Blood, 2008, 112, 4878-4878.	0.6	1